The George Institute For Global Health
Global
United Kingdom
India
China
Australia

News and Events

Media release: 
25/04/2017

On 19 April 2017, Professor Craig Anderson, Executive Director of the George Institute China received a new appointment as a guest professor at Chengdu Medical College (CMC).

Media release: 
20/04/2017

Clinical Pathways for Acute Coronary Syndromes in China (CPACS-3) research from The George Institute China has revealed factors attributed to the higher in-hospital mortality of ST elevation myocardial infarction (STEMI) patients admitted during off-hour in comparison with those during regular hour.

Media release: 
12/04/2017

The George Institute, China has been selected as a finalist in the AustCham Westpac Australia-China Business Awards (ACBA) of 2017, in the Business Excellence for Sustainability, Diversity and Social Responsibility category.

Meet Yifei Zhao, Research Fellow at The George Institute China, who is currently involved in the Clinical Pathway for Acute Coronary Syndromes (CPACS) project and work related to a sub-project of hospital management.

Media release: 
28/03/2017

'Road to Hierarchical Diabetes Management at Primary Care Settings in China' (ROADMAP Study) trial test was completed at the project site located in Longyou County, Quzhou City, Zhejiang Province from March 21 to 24, 2017.

Media release: 
23/03/2017

A drug increasingly being prescribed for treating sciatica has been revealed to be no better than placebo, in new research from The George Institute for Global Health.

Media release: 
09/03/2017

The George Institute for Global Health (TGI) has renewed a Memorandum of Understanding (MOU) with Peking University Health Science Center (PUHSC). 

Meet Xiang Lan, Clinical Research Associate at The George Institute China.

Media release: 
10/02/2017

BEIJING – February 9, 2017– The Memorandum of Understanding (MOU) was signed between The George Institute for Global Health (TGI) and National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention (NCNCD, China CDC).

Media release: 
10/02/2017

A small but clinically important trial of a new ultra low-dose four-in-one pill to treat high blood pressure has produced remarkable results.

Pages